Relationship between duration and extent of oedema and visual acuity outcome with ranibizumab in diabetic macular oedema: A post hoc analysis of Protocol I data.

Srinivas R SaddaJoanna CampbellPravin U DugelNancy M HolekampSzilárd KissAnat LoewensteinAlbert Joseph AugustinVanessa ShihXiaoshu XuCharles C WykoffScott M Whitcup

Published in: Eye (London, England) (2019)

Macular oedema exposure over the first 52 weeks of ranibizumab treatment is a negative prognostic factor for long-term visual acuity improvement in centre-involved DMO.

Keyphrases

diabetic retinopathy
age related macular degeneration
prognostic factors
optical coherence tomography
randomized controlled trial
type diabetes
cataract surgery
electronic health record
machine learning
artificial intelligence
preterm birth